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Abstract 
 
We employed a Hidden-Markov-Model (HMM) algorithm in Loss of Heterozygosity 
(LOH) analysis of high-density Single Nucleotide Polymorphism (SNP) array data 
from Non-Hodgkin´s lymphoma (NHL) entities, Follicular Lymphoma (FL) and Diffuse 
Large B-cell Lymphoma (DLBCL). This revealed a high frequency of LOH over the 
chromosomal region 11p11.2, containing the gene encoding the protein tyrosine 
phosphatase receptor type J (PTPRJ). Although, PTPRJ regulates components of 
key survival pathways in B-cells (i.e. BCR, MAPK and PI3K signaling), its role in B-
cell development is poorly understood. LOH of PTPRJ has been described in several 
types of cancer but not in any hematological malignancy. Interestingly, FL cases with 
LOH exhibited down-regulation of PTPRJ, in contrast no significant variation of 
expression was shown in DLBCLs. Additionally, sequence screening in exons 5 and 
13 of PTPRJ identified the G973A (rs2270993), T1054C (rs2270992), A1182C 
(rs1566734) and G2971C (rs4752904) coding SNPs (cSNPs). The A1182 allele was 
significantly more frequent in FLs and in NHLs with LOH. Significant over-
representation of the C1054 (rs2270992) and the C2971 (rs4752904) alleles were 
also observed in LOH cases. A haplotype analysis also revealed a significant lower 
frequency of haplotype GTCG in NHL cases, but it was only detected in cases with 
retention. Conversely, haplotype GCAC was over-representated in cases with LOH. 
Altogether, these results indicate that the inactivation of PTPRJ may be a common 
lymphomagenic mechanism in these NHL subtypes and that haplotypes in PTPRJ 
gene may play a role in susceptibility to NHL, by affecting activation of PTPRJ in 
these B-cell lymphomas. 
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INTRODUCTION 
 
Non-Hodgkin’s Lymphoma represents a heterogeneous group of lymphoid-derived 
hematological neoplasms (Swerdlow et al., 2008; Turner et al., 2010). Diffuse Large 
B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL), two of the most common 
NHL subtypes, are originated from germinal centre B-cells, but differ in morphology, 
tumor biology and aggressiveness (Klein and Dalla-Favera 2008) . However, despite 
their clinical disparities, there are a number of shared molecular pathogenic 
mechanisms of these diseases, and approximately 20% of FLs transform to DLBCL 
by acquiring a diverse number of genomic alterations during malignant B-cell 
development (Martinez-Climent et al., 2003; Green et al., 2011).  Because of the 
biological and genomic complexity observed among NHL subtypes, an 
understanding of their pathogenesis and etiology is still limited. Therefore, a better 
knowledge of common pathogenic mechanisms involved in NHL lymphomagenesis 
is biologically and clinically relevant. 
 
Loss of heterozygosity (LOH) analysis through comparison of the heterozygosity of 
genetic markers, such as microsatellite and single nucleotide polymorphism (SNP) 
markers, in tumor DNA with reference to matched normal DNA can be used for the 
identification of novel tumor suppressor genes (TSGs). Genetic inactivation of TSGs 
is understood to be caused by copy-neutral (chromosomal duplications, genomic and 
epigenetic mutations) or copy-loss (hemizygous deletions) events (Beroukhim et al., 
2006). The identification of TSGs in tumor tissue in the absence of a normal germ-
line counterpart has been limited due to the absence of available germ-line DNA or 
proper statistical approaches that allow inference of germ-line heterozygous data. 
Nonetheless, the implementation of Hidden Markov model (HMM) or cohort 
heterozygosity comparison (CHC) approaches in the analysis of SNP array data 
from unpaired tumor DNA samples has permitted the detection of LOH regions and 
possible TSGs that might be implicated in the origin and development of cancer 
(Beroukhim et al., 2006; Green et al., 2010). Using this HMM approach, we identified 
common LOH regions across the genome of DLBCL and FL tumors including 
11q11.2, targeting the PTPRJ gene.  
 
Protein tyrosine phosphatase receptor type J (PTPRJ) is a type III receptor-like 
tyrosine protein phosphatase (RPTP), which contains an extracellular receptor 
composed by 8 fibronectin type III-like domains, a transmembrane region and a 
single phosphatase catalytic domain (Ostman et al., 1994). Several lines of evidence 
have shown that PTPRJ-induced dephosphorylation negatively regulates MAPK 
(ERK1/2), PLCG1, PI3K (p85), FLT3, B-cell receptor (BCR), PDGFRB and VEGFR2 
signaling, acting as a tumor suppressor gene by controlling signaling pathways of 
cell growth, proliferation and angiogenesis (Kovalenko et al., 2000; Baker et al., 
2001; Lampugnani et al., 2003; Tsuboi et al., 2008; Zhu et al., 2008; Sacco et al., 
2009; Arora et al., 2011). Recently, Syndecan-2 (SDC2), a transmembrane heparan 
sulfate proteoglycan that induces cell adhesion, and Thrombospondin-1 (THBS1), a 
homotrimeric glycoprotein that inhibits cell growth and angiogenesis, were revealed 
as natural ligands of PTPRJ (Whiteford et al., 2011; Takahashi et al., 2012). A recent 
study has also found that PTPRJ is negatively regulated by the oncogenic effect of 
microRNA-328 expression in cervix and breast adenocarcinomas cell lines (Paduano 
et al., 2012a).  
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Loss of heterozygosity of PTPRJ has been previously reported in breast, lung, 
colorectal, thyroid and meningioma cancers, and implicated in the oncogenesis of 
these tumors (Ruivenkamp et al., 2002; Ruivenkamp et al., 2003; Iuliano et al., 2004; 
Petermann et al., 2011). Genetic inactivation of PTPRJ has not been described in 
any hematological malignancy, but this TSG has been described as a susceptibility 
gene in chronic lymphoid leukemia (CLL) and recently in childhood acute 
lymphoblastic leukemia (ALL) cases with ETV6-RUNX1 genic rearrangements, 
indicating an important role of this RPTP in the biology of the lymphocyte and its 
malignant transformation (Sellick et al., 2007; Ellinghaus et al., 2012). Other protein 
tyrosine phosphatases (PTPs), such as PTPRC (CD45) and PTPRO, have been 
implicated in the lymphocyte biology by their crucial role in the regulation of key 
survival B-cell BCR-mediated signals through PTP-mediated dephosphorylation of 
SFKs and SYKs (Zhu et al., 2008; Juszczynski et al., 2009).  
 
Although, studies on murine models and human cell lines have shown a possible 
regulatory role of PTPRJ throughout lymphocyte maturation and immunoresponse, 
its role in the B-cell development is still unknown (Tangye et al., 1998b; Lin et al., 
2004). PTPRJ is moderately expressed in B-cells and upregulated once T-cells are 
activated. In T-cells, PTPRJ inhibits the TCR-mediated T-cell activation by 
dephosphorylation of LAT and PLCG1 pathways (Tangye et al., 1998b; Baker et al., 
2001). A recent study determined that PTPRJ is commonly expressed in the T, NKT, 
NK, B, immature DC, macrophage, mast, and neutrophil cells; however, PTPRJ 
showed a higher expression in B-cells than in macrophages (Arimura and Yagi 
2010). Conversely, in mature B-cell malignancies, a lower expression of PTPRJ has 
been shown in DLBCLs and FLs, in contrast to its higher expression in Mantle-cell 
lymphomas (MCLs) (Dong et al., 2002; Miguet et al., 2009).  
 
Coding SNPs (cSNPs) in PTPRJ have been identified in colorectal and thyroid 
tumors as well as preferential allelic loss in patients with LOH (Ruivenkamp et al., 
2002; Iuliano et al., 2004). Susceptibility studies with PTPRJ-mapping SNPs have 
associated variants with increased cancer-risk in lung squamous cell, colorectal and 
papillary thyroid carcinomas (Iuliano et al., 2010; Mita et al., 2010). Furthermore, 
Lesueur et al., (2005) found association between a PTPRJ haplotype and cancer-
protection in breast cancer but the same haplotype did not have any effect in 
colorectal cancer susceptibility (Lesueur et al., 2005; Toland et al., 2008).  
 
In the present study, using a high resolution LOH approach we identified that loss of 
heterozygosity of PTPRJ is a common event across NHL cases. Moreover, we also 
detected a lower transcript abundance of PTPRJ in FL cases with LOH than those 
with retention (RET) of PTPRJ. Additionally, the following PTPRJ-targeting cSNPs 
were identified in our population: G973A (rs2270993), T1054C (rs2270992), A1182C 
(rs1566734) and G2971C (rs4752904). However, we also observed a higher 
frequency of the A1182 (Gln276) allele in FLs, an over-representation of C1054, 
A1182 (Gln276) and C2971 (Asp872) alleles in NHL cases with LOH, and a high 
frequency of haplotype GCAC in cases with LOH. These results highlight the use of 
high-resolution LOH approaches in the identification of TSGs that may have an 
impact in normal and malignant B-cell development and the study of cSNPs that may 
modulate the anti-tumor functions of PTPRJ in NHL.  
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MATERIALS AND METHODS 
 
Patients and control 
Fresh-frozen tumor biopsies from 20 Diffuse Large B-cell Lymphoma and 24 
Follicular Lymphoma patients and formalin fixed paraffin embedded tissue (FFPE) 
samples from 48 DLBCL cases were obtained as previously described (Green et al., 
2011; Keane et al., 2011). This research was approved by the human research ethic 
committees of each of the participating sites. Peripheral blood samples and normal 
hyperplastic lymphoid tissue (HLT) were obtained from Australian Leukemia and 
Lymphoma Group (ALLG) Tissue Bank (Princess Alexandra Hospital, Queensland, 
Australia), Gold Coast Hospital (Queensland Health, Australia) and Genomics 
Research Centre Clinic (Griffith University, Queensland, Australia). Genomic DNA 
and total RNA were isolated as previously described (Green et al., 2010; Green et 
al., 2011; Keane et al., 2011). 
 
High Resolution LOH analysis  
Genomic DNA from 21 DLBCL and 21 FL cases was analyzed using Affymetrix 250 
K Sty SNP microarrays, as previously described (Green et al., 2011). Raw data is 
publicly available through the gene expression omnibus (GEO), accession no. 
GSE22082. SNP genotyping and HMM-based LOH analysis were performed using 
GeneChip Genotyping Software (GTYPE; Affymetrix), following methodology 
previously described for inferring LOH of unpaired LOH tumor samples (Beroukhim 
et al., 2006; Green et al., 2010). dChipSNP and Integrative Genomics Viewer (IGV  
1.5)  programs were utilized to visualize the inferred LOH regions and select genes 
that were targeted in LOH regions with a frequency of LOH calls higher than 25% 
(Robinson et al., 2011). False Discovery Rates (FDR) Q-values from Genomic 
Identification of Significant Targets in Cancer (GISTIC) analysis of significant DNA 
copy number alterations were used to determine the probability of copy-loss 
(deletions) events in the evaluated regions (Green et al., 2011).  
 
In order to select candidate genes for further analysis and to avoid the false positive 
calls intrinsic to this unpaired HMM-based LOH approach (Beroukhim et al., 2006; 
Heinrichs et al., 2010), we performed a microsatellite validation of five LOH regions 
(data not shown). The selection of candidate genes within those regions was based 
on their significance in lymphocyte biology. A pair of microsatellites was chosen per 
candidate gene, based on their proximity to the candidate gene. Herein, we only 
show the microsatellite-based validation for PTPRJ.     
 
Microsatellite-based validation analysis  
Validation of PTPRJ HMM-based LOH results was carried out by fragment analysis 
of microsatellites targeting PTPRJ (D11S1350 and D11S4183). DNA samples from 
115 controls (24 Normal hyperplastic lymphoid tissue and 91 peripheral blood 
samples) and 92 NHL patients (68 DLBCL and 24 FL) were evaluated. 
Oligonucleotides sequences were taken from uniSTS database of NCBI. All PCR 
reactions were optimized in a final volume of 20 µL containing 50 ng of genomic 
DNA, 1X Colourless GoTaq® Flexi Buffer (Promega), 2 mM of MgCl2, 400 µM of 
dNTPs, 500 nM of each FAM-labeled primer and 0.05 units of GoTaqTM DNA 
Polymerase (Promega). DNA was amplified using temperature cycles consisting of 
an initial denaturation step of 95oC for 3 mins, followed by 40 cycles of 95oC for 30 
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secs, 55-62oC for 30 secs, and final step of 72oC for 30 secs. Fragment analysis of 
alleles and genotypes for each microsatellite were determined by GeneScan® 3130 
(Applied Biosystems, Austin, TX, USA), following manufacturer´s guidelines.  
 
Hardy-Weinberg Equilibrium (HWE) was confirmed in the control population using 
GenePop software (version 4.0.10). A 1-sided Pearson’s Chi-square test with 
correction for continuity was carried out to compare heterozygosity frequencies of 
D11S1350 and D11S4183 microsatellites between controls and NHL cases. The 
significance level was set at α < 0.05.  
 
PTPRJ expression analysis  
Previously published normalized mean fluorescence intensity values for PTPRJ, 
from an Illumina Sentrix Human-6 (v2.0) Expression Beadchip, from cases with a 
known LOH status (14 FLs and 17 DLBCLs), were used to determine the effect of 
LOH on PTPRJ expression in our cohort. Normalization of this microarray data was 
performed as previously described by Green et al., (2011). Cell-of-Origin (COO) sub-
classification of DLBCL samples was inferred from whole gene expression data of 21 
DLBCL cases (Green et al., 2011), following the criteria established by Shipp et al., 
(2002). Based on this analysis, 10 out 21 DLBCL cases were classified as GCB-like 
subtype and 11 out of 21 as non-GCB-like subtype.     
 
Validation of PTPRJ transcript abundance in cases with LOH and RET calls was 
carried out using quantitative PCR (qPCR). Total RNA from tonsils samples of 6 
healthy individuals and from 41 NHL tumor tissues (20 FLs and 21 DLBCLs) with 
HMM-based LOH data, were reverse transcribed to cDNA using QuantiTect Reverse 
Transcription Kit (Qiagen) (Green et al., 2011)). Transcript abundance of PTPRJ in 
controls and NHL cases was determined by relative quantification (∆∆Ct method) of 
PTPRJ expression normalized to RPL13A. The set of primers targeting PTPRJ 
specifically amplify the isoform 1 transcript, as only this isoform contains the region 
encoding the catalytic domain.  Sequences of oligonucleotides were: PTPRJ-F (5’-
CAGACCCATTCAACGGATGAC-3’), PTPRJ-R (5’- 
GTGTTCGGTAAAGGTCCTTGTGT-3’), RPL13A-F (5’-
ATCTTGTGAGTGGGGCATCT-3’) and RPL13A-R (5’-
CCCTGTGTACAACAGCAAGC-3’). Standard qPCR reactions were carried out in 
triplicate, in a final volume of 10µL containing 20 ng of input RNA, 200 nM of each 
oligonucleotide and 1X GoTaq® qPCR Master Mix (Promega). Cycling conditions 
and fluorescence detection was performed on a ABI 7900HT Real-Time PCR system 
(Applied Biosystems, Austin, TX, USA) with an initial denaturation of 95ºC for 3 min, 
followed by 40 cycles of 95ºC for 15 secs, and 60ºC for 1 min. Expression levels of 
PTPRJ, from genome-wide profiling and qPCR data, were compared between NHL 
cases with LOH and RET calls using an independent t-test (α < 0.05). 
 
Sequence analysis  
Exons 5 and 13 of PTPRJ were sequenced in gDNA samples from 44 controls, 24 
FL and 23 DLBCL cases. Sequences of oligonucleotides were: Exon 5-F (5’-
GAAGGTGACTGCATATATCT-3’), exon 5-R (5’-AGAACATTTAGTTACTGAAAG-3’), 
exon 13-F (5’-CTGCCATCACTTTCTTATGAT-3’) and exon 13-R (5’-
CCCAAAGAGTAAGAACCAGA-3’). Bidirectional direct sequencing of 40 ng of 
cleaned PCR amplicon was carried out using BigDye Terminator cycle sequencing 
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kit v3.1 in a GeneScan® 3130 (Applied Biosystems, Austin, TX, USA), following 
manufacturer’s guidelines.  
 
A 2-sided Pearson’s Chi-square test with correction for continuity or a Fisher’s exact 
test was used to compare allelic and genotypic frequencies of cSNPs between 
controls and cases, and between cases with LOH and RET calls, respectively.  
Additionally, 2-sided Pearson’s correlation was performed between alleles and 
genotypes of evaluated cSNPs between cases with LOH and RET calls. Linkage 
disequilibrium and comparison of haplotypic frequencies were carried out using 
Haploview 4.2 software (Broad Institute, 2010). Prediction of effect of cSNPs on 
protein function was performed using Sorting Intolerant From Tolerant (SIFT version 
4.0.3) (Kumar et al., 2009) and SNPs3D (Yue et al., 2006) online tools. 
 
 
RESULTS 
 
High resolution LOH analysis identifies common LOH regions across NHL 
entities, and implicates LOH of PTPRJ as a common event in DLBCL and FL 
 
The implementation of the HMM algorithm for LOH analysis allowed the identification 
of common LOH regions across DLBCLs and FLs (Figure 1, Table 1, Table S1). 
Notably, regions with known single-copy loss and mutations in DLBCL, such as 
TP53BP1 and EP300, respectively (Takeyama et al., 2008; Morin et al., 2011; 
Pasqualucci et al., 2011a), were identified by our LOH analysis, thus validating our 
HMM-based approach (Table S1). This high resolution approach identified LOH of 
11q11.2 as one of the commonly affected regions across all cases. Within this 
region, the PTPRJ gene was the most attractive candidate tumor suppressor gene, 
due to is well established role in regulating lymphocyte signaling. LOH of PTPRJ was 
present in 38% (16/42) of all cases; 33% (7/21) of DLBCL cases and 43% (9/21) of 
FL cases (Figure 2).  
 
Unpaired LOH analysis with microsatellites validates the HMM-based LOH 
findings  
Validation of the high resolution LOH findings for PTPRJ was performed by a 
significant reduction of heterozygosity for D11S1350 between controls and total NHL 
cases, controls and FLs, and controls and DLBCLs (P = 0.002; P = 0.002; P = 0.022, 
respectively) (Table 2). Conversely, non-significant differences were observed for 
D11S4183 between heterozygosity of controls and NHL cases. Discordances 
between these microsatellites are probably due to their positioning in relation to 
PTPRJ  locus, being the result from microsatellite D11S1350 the most informative as 
it is located within PTPRJ locus (Figure 2). 
 
PTPRJ is down-regulated in FL cases with LOH of PTPRJ 
Using available PTPRJ mean fluorescence intensity values, from an Illumina Sentrix 
Human-6 (v2.0) Expression Beadchip, from patients with a known LOH status (31 
out of 42 NHL cases (Green et al., 2011), we could not observe any significant effect 
of LOH on the PTPRJ expression between NHL cases with RET and LOH calls (67.5 
vs. 54; P =  0.145); however a trend towards down-regulation of PTPRJ was 
observed in FL cases with LOH (Supplementary Figure 1). This down-regulation was 
only confirmed in FL cases (2.05 vs 1.16; P = 0.034) but not in DLBCL (1.88 vs. 1.84        
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P = 0.962) or NHL (1.96 vs. 1.48; P = 0.278) cases with retention or LOH calls, 
respectively, by assessing PTPRJ expression by qPCR in patients with available 
HMM-based LOH data (41 out of 42 NHL cases) (Figure 3). 
 
Another expression analysis performed on the DLBCL samples, considering the 
COO subtype, did not reveal significant changes in PTPRJ expression in GCB-like 
cases (1.7 vs. 2.4; P =  0.606) and in non-GCB-like cases (2.0 vs. 1.0; P =  0.369) 
with retention and LOH. Nonetheless, a trend towards PTPRJ up-regulation in GCB-
like cases and PTPRJ down-regulation in non-GCB-like cases can be observed in 
patients with LOH (Supplementary Figure 2). 
 
Allelic frequencies of cSNPs in the exons 5 and 13 of PTPRJ differ between 
NHL cases with loss of heterozygosity (LOH) calls versus those with retention 
(RET) calls 
 
Previous studies have associated cSNPs located in the exons 5, 6, 7 and 13 of 
PTPRJ with colorectal and thyroid carcinomas and some of these polymorphisms 
have been found more frequently in patients with LOH of PTPRJ (Ruivenkamp et al., 
2002; Iuliano et al., 2004). We performed a pilot study screening exons 5, 6, 7 and 
13 of PTPRJ in 12 cases (8 FL and 4 DLBCL). This identified only the cSNPs G973A 
(Glu206), T1054C (Thr233) and A1182C (Gln276Pro), located in the exon 5, and 
G2971C (Glu872Asp), located in exon 13 of the PTPRJ gene (Table S2). Thereafter, 
we focused our analyses to exons 5 and 13 in an extended cohort of controls (n=44), 
FL (n=24) and DLBCL (n=23) cases, and compared their genotypic and allelic 
frequencies between these cohorts. However, only the A1182 (Gln276) allele was 
found to be significantly more frequent in FL cases than in controls (P = 0.045) 
(Table 3; Supplementary Table 3).  
 
Allelic distribution of the 4 cSNPs was investigated in cases with HMM-inferred LOH 
calls, by comparing genotypic and allelic frequencies of G973A (rs2270993), T1054C 
(rs2270992), A1182C (rs1566734) and G2971C (rs4752904) in DLBCL and FL 
cases with LOH or retention (RET) calls (Table 4; supplementary Table 4). Overall, 
genotypic and allelic frequencies of rs2270992, rs1566734 and rs4752904 were 
highly significant between cases with LOH and RET calls. For rs2270992, a 
significant over-representation of C1054 versus T1054 allele was detected in 
patients with LOH (p<0.0001). The A1182 (Gln276) allele was always present in 
patients with LOH and in most of cases with retention of heterozygous status (P = 
0.033 and 0.023 respectively). Moreover, a highly significant over-representation of 
the C2971 (Asp872) allele was observed in the majority of cases with LOH 
(p<0.0001). A significant enrichment of homozygous for the wild type G973, A1182 
alleles and for the variant C1054 and C2971 alleles was observed in individuals with 
LOH (supplementary Table 4). 
 
Haplotype analysis of cSNPs on exon 5 and 13 of PTPRJ identified the 
presence of a cancer-protective haplotype (GTCG) and loss of haplotype 
GCAC in LOH cases. 
Linkage disequilibrium (LD) between rs1566734 and rs1503185 was previously 
determined in cases with thyroid carcinoma and adenoma (Iuliano et al., 2004). To 
investigate the possible LD among G973A (rs2270993), T1054C (rs2270992), 
A1182C (rs1566734) and G2971C (rs4752904) polymorphisms, we compared the 
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genotypic frequencies of these four cSNPs in controls. High LD values were 
observed among all 4 cSNPs, the lowest D’ value was observed between A1182C 
(rs1566734) and G2971C (rs4752904) polymorphism (D’=0.712, P = 0.008). Thus, 
this analysis provided good evidence of a single haplotype block at this locus, which 
contains n=7 and n=9 possible haplotypes in controls and cases respectively 
(Supplementary Table 5).  
 
Comparison of haplotypic frequencies at this locus between controls and cases 
revealed that haplotype GTCG was significantly less common in cases than in 
controls (17% vs. 6%; OR=0.33, 95% CI:0.09-0.72, P = 0.021). In NHL cases, this 
haplotype was absent in patients with LOH, in comparison to a frequency of 11.2% in 
patients with retention (χ2=3.869, P = 0.0492). Moreover, a highly significant 
frequency of haplotype GCAC was observed in cases with LOH than in those with 
RET calls (84% vs. 36%; χ2=18.662, P = 1.56 x 10-5) (Supplementary Table 5). This 
finding highlighted a significantly low frequency of the protective haplotype GTCG in 
NHL cases and confirms over-representation of haplotype GCAC in NHL patients 
with LOH and a preferential retention of haplotype GTCG in NHL cases.    
    
 
DISCUSSION 
 
The study of common genetic alterations across FL and DLBCL cases has revealed 
common pathogenic mechanisms that can underlie the malignant phenotype of 
these B-cell lymphomas and may open a new alternative in the discovery of more 
effective chemotherapeutic targets (Green et al., 2011). In the present study, the 
implementation of HMM-based LOH analysis on high-density SNP array data from 
unpaired DLBCL and FL cases allowed the identification of common regions with 
LOH across these NHL subtypes, suggesting that the inactivation of TSGs within 
these regions might be a common molecular mechanism in the lymphomagenesis 
and aggressiveness of DLBCL and FL, as well as in the transformation of FL to 
DLBCL.  
 
One of the common and most interesting LOH regions in NHL cases was mapped to 
the 11p11.2 locus, with PTPRJ identified as a potential TSG that could be inactivated 
in NHL lymphomagenesis. This is suggested by the significant down-regulatory 
effect of LOH of PTPRJ on its expression of PTPRJ in FL cases with LOH. However, 
it is still unclear whether events driving LOH in DLBCL cases may or may not induce 
an effect on PTPRJ expression in cases with GCB-like and non-GCB-like subtypes, 
due to the high heterogeneity of DLBCLs (Rosenwald et al., 2002; Pasqualucci et al., 
2011b). LOH of PTPRJ has been previously reported in breast, lung, colorectal, 
thyroid and meningioma cancers, but has not been described in any hematological 
malignancy and its effect on expression has not been determined (Ruivenkamp et 
al., 2002; Ruivenkamp et al., 2003; Iuliano et al., 2004; Petermann et al., 2011). 
However, it is important to highlight that two SNP-based predisposition studies have 
previously implicated PTPRJ in susceptibility to CLL and to ALL cases with the genic 
rearrangement ETV6-RUNX1. (Sellick et al., 2007; Ellinghaus et al., 2012). In the 
present study, LOH of PTPRJ was identified in 4 out 10 CLL cases (unpublished 
data). On the other hand, the association of PTPRJ to ETV6-RUNX1 genic 
rearrangements in ALL cases suggests that correlation analysis of LOH of PTPRJ 
with translocations occurring (i.e t(14;18), t(8;14), t(3;14) and others) in FLs and 
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DLBCLs is highly relevant, as these NHL subtypes have a high frequency of 
translocations (Rosenwald et al., 2002; Martinez-Climent et al., 2003; Morin et al., 
2011; Pasqualucci et al., 2011a). Altogether this evidence supports the role of this 
TSG in the etiology and malignant transformation of lymphoid-origin neoplasms. 
 
The effect that LOH of PTPRJ may have in B-cell derived neoplasms requires further 
investigation, as the role of PTPRJ in B-cell development has not been clearly 
determined. In normal B-cell development, PTPRJ (CD148) expression has been 
proposed as an antigen marker to differentiate human memory B-cells (PTPRJ+) 
from naïve B-cells (PTPRJ-) (Tangye et al., 1998a). However, in B-cell-derived 
neoplasms, PTPRJ expression was found to be heterogeneous across NHL 
subtypes, failing to classify lymphoid tissue with either memory B-cell or naïve B-cell 
origins. Furthermore, DLBCL and FL showed a lower and more diverse expression 
of PTPRJ in comparison with other NHL subtypes (MCL, CLL, BL, MALT and 
plasmacytoma) (Dong et al., 2002). In another study, PTPRJ expression has been 
proposed as a useful diagnostic marker for mantle cell lymphomas (MCL), based on 
its higher expression in MCLs than in CLLs and in SLLs (Miguet et al., 2009).  
 
Although functional studies are required to determine whether LOH-driving events 
induce inactivation of PTPRJ in NHL, several lines of evidence support the 
hypothesis that LOH of PTPRJ might act as an oncogenic hit in the 
lymphomagenesis or progression of FLs and DLBCLs. This is based on the fact that 
this receptor-like protein tyrosine phosphatase (RPTP) negatively regulates key 
signaling for the survival and development of B-cells, such as: MAPK (ERK1/2) 
PLCG1, PI3K (p85), and B-cell receptor (BCR) signaling (Baker et al., 2001; Tsuboi 
et al., 2008; Zhu et al., 2008; Sacco et al., 2009). Interestingly, MAPK pathway has 
been recently identified as a common target of genetic alterations (amplification and 
deletions) across NHL entities (DLBCL, FL and CLL), suggesting that its 
deregulation might be critical for pathogenesis of these NHL lymphomas (Green et 
al., 2011). The significant PTPRJ down-regulation observed in FL cases with LOH 
also suggests that inactivation of PTPRJ might enhance oncogenic activity of MAPK 
signaling as PTPRJ mediates the direct dephosphorylation and inactivation of pro-
proliferation ERK1/2 kinases (Sacco et al., 2009). Other lines of evidence show that 
PTPRJ also regulates the PI3K signaling pathway by direct dephosphorylation of 
p85, which is phosphorylated by SCR kinase and is simultaneously activated by 
PTPRJ to induce immunoreceptor signaling in B-cells and transition from pro-B to 
pre-B-cell (Saijo et al., 2003; Tsuboi et al., 2008; Zhu et al., 2008). Furthermore, an 
overlap of the roles of PTPRJ (CD148) and PTPRC (CD45) in B-cells and 
macrophages has been observed in knock-out (KO) experiments. In double KO 
mice, a severe myeloproliferative disease and a partial block of B-cell development 
with impairment of B-cell receptor and immunoreceptor signaling was caused by 
failure in PTPRJ-mediated and PTPRC-mediated dephosphorylation of the inhibitory 
phophotyrosine residue of SRC kinase (Zhu et al., 2008). Hence, it can be 
hypothesized that the effect of LOH of PTPRJ in NHL cases would be less 
deleterious than in cases with loss of both PTPRJ and PTPRC, due to their 
overlapping function. However, LOH of PTPRC was not observed in our cohort of 
NHL samples (data not shown). This finding instead suggests that PTPRJ might act 
as a low-penetrance gene in DLBCLs and FLs, similar to previous findings in thyroid 
and colorectal cancers (Ruivenkamp et al., 2002; Iuliano et al., 2004).   
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The molecular mechanisms that underlie the LOH-induced inactivation of PTPRJ in 
tumors are still unclear and require further investigation. The very low frequency of 
deletions in the PTPRJ locus across NHL cases and the observed reduction in the 
expression of PTPRJ in FL cases with LOH, suggest that, in our cohort of NHLs, 
LOH is driven by copy-neutral events, which might alter transcriptional or 
translational regulatory mechanisms of PTPRJ. One of these mechanisms could be 
the microduplication of the genomic region between exon 1 and 11, upstream of 
PTPRJ, as it has been shown to induce epigenetic silencing of the normal PTPRJ 
CpG island in patients with early-onset familial colorectal cancer; however, its effect 
on expression has not been studied (Venkatachalam et al., 2010). Moreover, it is has 
been revealed that PTPRJ expression could be also impaired by a translation 
attenuation mechanism, caused by the presence of alternative short upstream ORFs 
(uORFs) at the 5´end of PTPRJ (Karagyozov et al., 2008). It is possible that LOH-
driving events use this mechanism to induce under-expression of PTPRJ, as low 
expression of PTPRJ was detected in meningioma cases with LOH (Petermann et 
al., 2011) and in a DLBCL cell line with LOH (unpublished data). Although somatic 
mutations are known as LOH-driving events, Ruivenkamp et al., (2002) failed to 
identify mutations after direct sequencing of the 25 exons of PTPRJ in NHL cases 
with and without LOH, indicating that mutations are not a driving cause of LOH of 
PTPRJ. This finding is supported by the low frequency of mutations observed in 
other types of cancer and the absence of mutations in recent exome sequencing of 
NHL tumors. (Forbes et al., 2011; Morin et al., 2011; Pasqualucci et al., 2011b). 
Nonetheless, mutations might have a dominant negative effect on the anti-tumor 
activity of this RPTP, as cell lines with a single copy of a deleterious mutation or 
deletion in the PTPRJ catalytic domain failed to respond to the PTPRJ-targeting 
antibody, Ab1, and were unable to restore the PTPRJ-associated dephosphorylation 
of downstream pathways (ERK1/2 and MET kinases) (Takahashi et al., 2006). 
Further mutational screening, epigenetic, and functional studies will be required to 
determine the driving cause of LOH in NHLs.  
 
Previous sequence screenings have associated cSNPs located in exons 5, 6, 7 and 
13 of the PTPRJ gene with colorectal and thyroid carcinomas (Ruivenkamp et al., 
2002; Iuliano et al., 2004). In this study, cSNPs located within exons 5 and 13 of 
PTPRJ were identified in NHL cases and the Gln276 allele (A1182) was the only 
allele to be significantly more common in FL cases and controls. Nonetheless, a 
highly significant over-representation of the rare C1054 allele, the potentially 
protective Gln276 allele (A1182), and the potentially cancer-risk Asp872 allele 
(C2971) were observed in cases with LOH. In thyroid carcinomas, combination of 
homozygous for Gln276Pro, Arg326Gln and Glu872Asp polymorphisms were 
significantly more frequent in patients than in healthy individuals but not for each 
polymorphism (Iuliano et al., 2004). Haplotypes from a single haplotype block of 
PTPRJ were also identified by the allelic combination of the polymorphisms G973A 
(rs2270993), T1054C (rs2270992), A1182C (rs1566734), and G2971C (rs4752904) 
in controls. Haplotype GTCG was found to confer a protective effect for DLBCL and 
FL lymphomagenesis as it was more frequent in controls than in cases. The fact this 
haplotype was only found in patients with retention calls confirms this effect. In 
addition, a significant over-representation of the haplotype GCAC was observed in 
cases with LOH of PTPRJ, which both validates the analysis performed individually 
for each cSNP and indicates that this haplotype may have a higher effect on the 
function of PTPRJ than each polymorphism separately.  
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The effect of these cSNPs, individually or in a haplotype block, on the 
oligomerization and function of PTPRJ, and their relationship with LOH status in FL 
and DLBCL lymphomagenesis requires further study. However, it is noteworthy to 
mention that all analyzed cSNPs are located in encoding regions of Fibronectin type 
III domains, which are part of the ectodomain of PTPRJ. Particularly, the Gln276Pro 
(A1182C) polymorphism is a non-conservative substitution located in the exon 5, 
which partially encodes the second Fibronectin type III (FNIII) domain of PTPRJ, and 
which induces a torsional stress that potentially could affect the conformation of 
ectodomain receptor (Ruivenkamp et al., 2002). Conversely, the presence of the 
Gln276Pro polymorphism was predicted to have a no deleterious effect on the 
PTPRJ function. Previous association studies have linked Gln276Pro polymorphism 
with cancer. In this matter, the Gln276 allele failed to confer protection or 
susceptibility to colorectal cancer; however, significant association was observed 
between Gln276Pro and/or Arg326Gln alleles with susceptibility to lung squamous 
cell carcinoma and colorectal cancer (Mita et al., 2010) 
 
Interestingly, the A1182 allele (Gln276) was over-represented in FL and DLBCL 
cases with LOH, which was also found in colorectal patients with LOH (Ruivenkamp 
et al., 2002). The retention of the C1182 (Pro276) allele in patients without LOH is 
intriguing as this variant may have an adverse effect on oligomerization and 
activation of PTPRJ, and consequently, may cause a constitutive activation of 
PTPRJ-regulated oncogenic pathways (MAPK, PI3K, PLCG1 and B-cell receptor). 
This hypothesis was also suggested for an in vivo study, as the Gln276Pro 
polymorphism is located in the encoding region of the antibody-targeted epitope. In 
this study, the antibody-mediated activation of PTPRJ inhibited angiogenesis and 
endothelial cell growth (Takahashi et al., 2006). The presence of this polymorphism 
in this epitope suggests that those cases with retention of Pro276 allele might have 
an adverse effect on the cellular response to this antibody. Furthermore, the high 
frequency observed of the wild-type Gln276 allele in FLs correlates to its indolent 
clinical course and suggests that the PTPRJ response to either its endogenous 
ligand or Ab1-like antibodies would be more sensitive than in those harboring the 
Pro276 allele.  
 
Another interesting cSNP in this study was the G2971C (Glu872Asp) polymorphism. 
This polymorphism is a conservative substitution located in the encoding region of 
the 8th FNIII domain, which was predicted to cause a deleterious effect on the protein 
structure stability.  Despite allelic and genotypic frequencies of G2971C (Glu872Asp) 
were not significant between controls and NHL cases, a highly significant over-
representation of C2971 (Asp872) allele was observed in cases with LOH. 
Conversely, significant allelic retention of Asp872 allelic was found in thyroid 
carcinomas (Iuliano et al., 2004). Based on this, it may be possible that this cSNP 
might be associated with lymphomagenesis of DLBCL and FL. In another study, the 
Asp872 allele has been found to confer high risk to papillary thyroid carcinoma 
(Iuliano et al., 2010). Additionally, allele-specific epigenetic silencing of the 
potentially protective Glu872 allele caused by transcriptional read-through due to a 
microduplication upstream of PTPRJ promoter was observed in a patient with early-
onset familial colorectal cancer (Venkatachalam et al., 2010). Hence, this finding 
suggests that the Asp872 allele might be preferentially expressed in cases with this 
microduplication and in cases with LOH.    
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Recent studies have also provided evidence that support the implication of PTPRJ in 
lymphomagenesis. Syndecan-2 (SDC2) and Thrombospondin-1 (THBS1) have been 
recently described as PTPRJ ligands, but its role in the lymphomagenesis of FL and 
DLBCL is still unclear (Whiteford et al., 2011; Takahashi et al., 2012). Nonetheless, it 
is noteworthy to mention that NHL cases who express THBS1 tend to exhibit shorter 
survival rates than those who do not express it (Paydas et al., 2008; Paydas et al., 
2009). Hence, further studies focused on studying the role of PTPRJ and its ligands 
(i.e. SDSC2 and THBS1) in the development of the lymphocyte as well as in the 
lymphomagenesis of FL and DLBCL will be highly relevant.  
 
Additionally, based on the tumor suppressor activities of PTPRJ in controlling 
pathways responsible for cell proliferation, apoptosis, angiogenesis and cell 
adherence, we conclude that PTPRJ is a promissory target for novel and more 
effective anti-cancer therapies (Takahashi et al., 2006; Paduano et al., 2012b). 
Interestingly, PTPRJ and anti-CD20 (Rituximab), the standard anti-NHL treatment, 
regulate PI3K and MAPK signaling at different targets (Vega et al., 2004; Suzuki et 
al., 2007; Tsuboi et al., 2008; Sacco et al., 2009). Therefore, it is important to study 
the genetics mechanisms that govern the expression or might disrupt the function of 
PTPRJ in NHL. 
 
In summary, high-resolution LOH approaches have not only successfully identified 
LOH of PTPRJ as a common TSG-inactivating mechanism in NHL but have also 
implicated PTPRJ in the etiology and lymphomagenesis of NHL. This finding is 
confirmed by down-regulation of PTPRJ in FL cases with LOH, over-representation 
of cSNPs and haplotypes in patients with LOH. It is hypothesized that retention of 
these cSNPs could alter the ligand-mediated activation of PTPRJ and its subsequent 
downstream signaling; therefore, this could also affect the response of this protein 
tyrosine receptor to potential PTPRJ-specific immunotherapies that target epitopes 
harbouring cSNPs.  
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Figure legends  
 
Figure 1. High resolution (HMM) whole genome LOH analysis on Affymetrix 250 K 
Sty SNP microarray data from unpaired 42 NHL tumor samples inferred common 
LOH regions across NHL cases (Upper panel). Loss of heterozygosity of PTPRJ and 
implicated this TSG as common target of lymphomagenic hits in NHL (gray-
highlighted region). In the present study, the loss of heterozygosity of TP53BP1 gene 
was used as a sanity-check marker. Copy-loss events in LOH regions were 
examined by plotting GISTIC FDR scores for deletions derived from Green et al., 
(2011) (Lower panel). Regions with a frequency higher than 25% were considered as 
common LOH regions. Deletions were identified by a GISTIC score higher than 0.01. 
Information about common LOH regions is detailed in Supplementary Table 1.      
 
Figure 2. High resolution LOH analysis across chromosome 11 inferred LOH 
regions. A) Loss of Heterozygosity of PTPRJ gene is a common event (Upper panel) 
and is not caused by copy-loss events in NHL cases (lower panel). B) Chromosomal, 
genetic and transcript mapping of PTPRJ gene indicating location of microsatellites 
(D11S1350 and D11S4183) that were used to validate LOH in PTPRJ locus.  
 
Figure 3. Down-regulation of PTPRJ was observed in FL cases with LOH, 
suggesting that LOH in this NHL subtype is caused by LOH expression-affecting 
mechanisms (i.e. epigenetic silencing). Transcript abundance of PTPRJ was 
assessed by qPCR in A) NHL (n=41), B) FL (n=20) and C) DLBCL (n=21) cases with 
loss of heterozygosity (LOH) or retention (RET) of PTPRJ. A significant 1-fold 
decrease of PTPRJ expression was observed in FL cases with LOH (2.05 vs 1.16;    
P = 0.034). Conversely, no significant differences in PTPRJ expression were found 
within NHL cases (1.96 vs. 1.48; P = 0.278) and within DLBCL cases (1.88 vs. 1.84 
P = 0.962) with RET and LOH calls.  
